Serum cystatin C is an early renal dysfunction biomarker in patients with hepatitis C virus

Nagwa Mohamed Assem¹, Amany Ibrahim Mohammed², Hamed Mohamed Abdel Barry², Ibrahim El Tantawy El Sayed² and Ibrahim Elmadbouh³*

Abstract

Background: Hepatitis C virus (HCV) may induce extrahepatic manifestations as acute or chronic renal dysfunction. The aim was to evaluate the diagnostic role of some biomarkers as cystatin C, cryoglobulins, rheumatoid factor (RF), and complement C3 for extrahepatic renal affection in newly diagnosed patients with HCV infection.

Methods: Blood and urine were collected from randomized individuals screened for new HCV infection (n=400). The studied populations were divided into 3 groups: control group I: thirty healthy individuals not suffering from either liver or kidney diseases, group IIa: thirty HCV patients who have positive HCV antibody test but showed negative PCR test, and group IIb: thirty HCV patients who showed positive results for both HCV antibody and PCR tests.

Results: In HCV group IIb, levels of serum total bilirubin, AST and ALT, and urine albumin/creatinine ratio were increased whereas serum albumin and creatinine clearance were decreased versus other groups. However, the levels of blood urea nitrogen and serum creatinine were still within the normal range in all groups. In HCV group IIb, cystatin C, cryoglobulins, and RF levels were increased; meanwhile, serum creatinine/cystatin C ratio and complement 3 levels were decreased compared to the other groups. HCV-infected patients significantly had higher serum cystatin C (>1.24 mg/L, \(P<0.001\)) and lower creatinine/cystatin C ratio (<70.1μMol/mg, \(P=0.002\)), and cystatin C was significantly correlated with liver and kidney parameters.

Conclusion: High serum cystatin C and low creatinine/cystatin C ratio may be early indicators of mild renal dysfunction with normal serum levels of creatinine in HCV-infected individuals.

Keywords: HCV, AKI, Cryoglobulins, Cystatin C, Complement C3, RF, PCR

Introduction

Acute hepatitis C virus (HCV) is a widespread infectious disease that affects the liver in about 200 million people worldwide [1] and progresses to chronic HCV in 50–80% of patients that may be leading to liver fibrosis, cirrhosis, hepatocellular carcinoma, and death [2]. However, there are also extrahepatic manifestations of chronic HCV which include glomerulonephritis, thyroiditis, insulin resistance, diabetes mellitus, porphyria cutanea tarda, lichen planus, vitiligo, seronegative arthritis, cryoglobulinemia, and lymphoproliferative disorders [3].

HCV-infected patients may present with acute kidney injury (AKI), chronic kidney disease (CKD), and end-stage renal disease (ESRD) within 5 years [3, 4]. Blood urea nitrogen (BUN), creatinine, and creatinine clearance (as an estimation of glomerular filtration rate, eGFR) are not sensitive or accurate for early kidney dysfunction (AKI) because these markers depend on diet and body metabolic and muscle condition [5–7].
Cystatin C is a potent inhibitor of lysosomal proteinases and probably one of the most important extracellular inhibitors of cysteine proteases [8–10]. Cystatin C has an advantage as low molecular weight (13.3 kilodaltons), produced at a constant rate in all nucleated cells, eliminated by glomerular filtration, reabsorbed, and catalyzed in renal proximal tubular cells [11]. Serum levels of cystatin C are independent of age, sex, and muscle mass and are not influenced by bilirubinemia, inflammation, or neoplasia [12]. Therefore, serum cystatin C could provide an alternative method to creatinine-based criteria for eGFR [12, 13]. Moreover, serum cystatin C has some advantages over the serum creatinine as a biomarker for eGFR [5], and it is elevated in early hepatic fibrosis [8] rather than early kidney disease [12].

Interactions between HCV and the host immune system may play an important role in the viral persistence of chronic HCV patients. The presence of extrahepatic parameters such as complement C3 [14, 15] and rheumatoid factor [16], cryoglobulins, and mixed cryoglobulins and cystatin C may be involved in renal injury [17].

The aim was to evaluate the diagnostic role of cystatin C and creatinine/cystatin C ratio, cryoglobulins, rheumatoid factor (RF), and complement C3 as early biomarkers of extrahepatic kidney dysfunction in newly diagnosed patients with HCV.

Material and methods

Patients

All subjects were selected from Menoufia University Hospital within the national campaign to combat virus C. Blood samples were taken from the brachial vein from all subjects and their laboratory analysis was done in Menoufia University Hospital and Medical Biochemistry Department, Faculty of Medicine, Menoufia University. Hospital’s Review Board has given ethics approval and all participants have written an informed consent prior to subject characterization and sample collections in accordance with the guidelines of the Declaration of Helsinki.

For the inclusion criteria, this cross-section study was performed on individuals (n = 400) in a health screening program for HCV infection between 2019 and 2021; all were males with age 35–45 years according to the results of hepatitis C virus antibody and PCR; the studied population was divided into 3 groups as follows: group I: 190 individuals who showed a negative result for HCV antibody test and 30 healthy individuals not suffering from both liver and kidney disease according to liver and kidney function parameter tests were chosen as a control group. HCV group II: 210 individuals showed a positive result for the HCV antibody test and were classified according to the results of the polymerase chain reaction (PCR) test for them. The result of PCR was as follows: 95 individuals showed a negative result for the PCR test and 115 individuals showed a positive result for the PCR test; 30 individuals from each of subgroup II not suffering from apparent kidney disease were chosen to be involved in this study, as group IIa and group IIb, respectively.

The exclusion criteria were hypertension, diabetes mellits, pre-existing kidney disease, established liver cirrhosis of different or mixed etiologies such as alcohol intake, hepatitis B, autoimmune liver disease, non-alcoholic fatty liver disease (NAFLD), hepatocellular carcinoma, abnormal thyroid function, or malignant diseases.

Laboratory analysis

The blood samples (10 mL) were centrifuged (4000 rpm for 10 min) for the collection of serum. Each serum sample was divided into two parts. The first part was directly stored at −80°C until assayed for quantitative estimation of HCV antibody levels and PCR assay. In the second part, serum samples were stored at −20°C for biochemical investigations. All sera were thawed at room temperature when ready for analysis. Urine 24-h samples were collected in a sterile plastic container for measuring urine creatinine and albumin.

Determination of liver and renal function tests

Serum total bilirubin, aspartate transaminase (AST), alanine transaminase (ALT), albumin, creatinine, and blood urea nitrogen (BUN) were determined using commercial kits on the Cobas e501 analyzer (Roche Diagnostics, Germany).

Urine albumin and creatinine were measured using commercial kits on the Cobas e501 analyzer (Roche Diagnostics, Germany) for urine albumin to creatinine ratio (30 mg/g or greater detection of albuminuria) [18].

The creatinine clearance was calculated from the formula:

\[
\text{Creatinine clearance (CrCl)} = \frac{\text{urine volume (V)} \times \text{urine creatinine concentration (U)}}{\text{serum creatinine concentration (P)} \times \text{serum volume (S)}}
\]

The estimated creatinine clearance is not normally physiologically greater than 120 mL/min for most adults.

Determination of HCV antibody concentration

Anti-HCV antibodies were determined using electrochemiluminescence immunoassay “ELISA” using Cobas 6000 (ROCHE, Germany). The assay procedure was carried out in a microwell coated with a combination of recombinant hepatitis C virus (rHCV) antigen (c22-3, c200, and NS5).

Determination of RT-qPCR for HCV RNA

The procedure involved 3 main steps: HCV RNA extraction, conversion of HCV RNA to complementary DNA
(cDNA), and amplification and detection of the amplified products. HCV RNA extraction was performed by using an Artus® HCV RG RT-PCR kit (Qiagen GmbH, Germany, Cat No. 4518263) according to the manufacturer's instructions. HCV levels were determined using the Rotor-Gene Q MDx (Rotor-Gene Q MDx, Qiagen, Germany) Light Cycler Real-Time PCR System using Rotor-Gene-3000 software version 6.0.23 under the following conditions: 50°C, 25 min; 94°C, 2 min; 5 cycles of 94°C for 10 s, 55°C for 15 s, and 72°C for 15 s; and 42 cycles of 94°C for 10 s, 60°C for 45 s, and 40°C for 30 s. Fluorescence was measured at 60°C for each cycle. An internal quality control serum was included during RT-PCR.

**Determination of serum cryoglobulins**

Cryoglobulins were determined by human enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (MyBioSource, San Diego, CA, USA).

**Determination of serum complement C3**

Serum complement component 3 (C3) levels were measured by the human ELISA technique (ab108823) (Abcam, Cambridge, MA, USA). Normal ranges of serum C3 levels were set at 80–160 mg/dL [19].

**Determination of serum rheumatoid factor (RF)**

Serum rheumatoid factor IgM were assayed by human rheumatoid factor IgM ELISA (Cell BioLabs Inc. USA) using reagents and controls supplied by the manufacturer with results considered positive when they exceeded values of 12 IU/mL [20].

**Determination of serum cystatin C**

Serum cystatin C was measured using a human ELISA assay (BioVender, Brno, Czech Republic). The creatinine/cystatin C ratio was calculated as the serum creatinine concentration (μMol/L) divided by the cystatin C concentration (mg/L) [21, 22].

**Statistical analysis**

The data were analyzed by SPSS statistical package version 20 on an IBM-compatible computer. Quantitative data were expressed as mean ± standard deviation and analyzed by applying Student's t-test, one-way ANOVA, and Tukey post hoc tests to determine significant differences among all groups. ROC curve was used to determine cutoff points, sensitivity %, and specificity % for quantitative variables of interest. Pearson correlation (r) was used to assess the correlation between variables' parameters. A P value of <0.05 was considered as being statistically significant.

**Results**

The laboratory results of HCV-infected patients (groups IIa and IIb) indicated a significantly higher serum total bilirubin, ALT, AST, BUN, creatinine, and urine albumin/creatinine ratio and a significantly lower serum albumin and creatinine clearance concentration as compared to the controls (Table 1). Despite serum creatinine and BUN levels were increased in both subgroups (IIa, IIb), as compared to the controls, these results are still within the normal range (Table 1).

The present study showed that HCV infection caused alterations in some extrahepatic parameters such as cryoglobulin formation in both groups IIa and group IIb where cryoglobulins were not detected in the controls (Table 1). Also, in both group IIa and group IIb, our data indicated a significantly increased rheumatoid factor and cystatin C and a significant decrease in complement C3 and creatinine/cystatin C ratio versus controls (Table 1).

HCV-infected patients had significantly higher serum cystatin C with cutoff value (> 1.24 mg/L, P <0.001) and lower creatinine/cystatin C ratio (< 70.1 μMol/mg, P = 0.002). Also, the area under the curve (AUC), 95% CI, sensitivity %, and specificity % are assessed and shown in Table 2 and Fig. 1.

Serum cystatin C was positively correlated with serum total bilirubin, ALT, AST, BUN, creatinine, cryoglobulins, RF, and urine albumin/creatinine ratio and was negatively correlated with serum albumin and creatinine clearance, complement C3 and creatinine/cystatin C ratio as shown in Table 3. Also, serum creatinine/cystatin C ratio was negatively correlated with serum total bilirubin, ALT, AST, cryoglobulins, RF, and urine albumin/creatinine ratio and was positively correlated with serum albumin and complement C3 as shown in Table 3.

**Discussion**

Renal function testing is important in monitoring and predicting the mortality in patients with chronic hepatitis with cirrhosis as in hepatorenal syndrome [23]. AKI is the most common extrahepatic manifestation associated with increasing mortality in patients with acute-on-chronic liver failure and often occurs with the serum creatinine level within the normal range, and the authors concluded that minor increases in serum creatinine are clinically relevant and can adversely affect survival [23, 24]. HCV may induce chronic liver fibrosis and kidney injury or hepatorenal syndrome through either direct viral invasion of the renal parenchyma [25, 26], glomerular immune complex deposition, renal complications of its extrarenal hepatic manifestations [27], or nephrotoxicity of drugs used for its treatment [3, 4]. Serum cystatin
C level was an indirect marker of liver fibrosis in several chronic liver diseases [8, 28].

Therefore, our aim was to assess the biomarkers helpful for the diagnosis of early renal dysfunction by testing for cryoglobulins, RF, complement C3, cystatin C, and creatinine/cystatin C ratio in newly diagnosed HCV-infected patients.

Cryoglobulins are immunoglobulins that precipitate or form a gel when exposed to temperatures below 37°C and re-solubilize when re-warmed in vitro [17]. Mixed cryoglobulins are potentially present during connective tissue and autoimmune diseases and chronic infections [25]. Mixed cryoglobulins can cause renal injury in almost 30% of cases with nephropathy called cryoglobulinemic glomerulonephritis [27]. Mixed cryoglobulins lead to chronic renal failure in 14% of cases within 6 years [29]. The kidney is one of the most easily involved organs in HCV-infected carries with risk for AKI such as cryoglobulinemic vasculitis and glomerulonephritis [30, 31].
Our study illustrated a significant difference in cryoglobulin concentration between groups IIa and IIb, while in the control group cryoglobulins were undetected and in groups IIa and IIb the level of cryoglobulins was significantly increased. This finding may be supported by many studies that reported the relationship between HCV infection and cryoglobulin formation [32–35].

The complement system is part of the innate and acquired immunity programs that clear pathogen components from an organism [36]. Therefore, complement C3, an acute-phase protein, is decreased in chronic HCV patients [14, 15, 37]. Complement C3 protein plays a pivotal role in both classical and alternative pathways of complement activation [37]. The complement system is involved in the pathogenesis of a variety of liver disorders, including viral hepatitis, liver injury and repair, fibrosis, alcoholic liver disease, and liver ischemic/reperfusion injury [37].

Our data indicated a statistically significant decrease in complement C3 concentration in groups IIa and IIb compared to the control group. This finding may be supported by many investigators who reported the HCV infection reduced serum complement C3 [38–41]. Serum complement C3 levels were depleted in HCV-infected cirrhotic patients [15]. Complement activation leads to a plethora of cellular responses ranging from apoptosis to opsonization [14, 36].

Polyarthritis as an extrahepatic manifestation involving small joints, which resembles rheumatoid arthritis, has been described in association with HCV infection [16]. Also, mixed cryoglobulins comprise an IgM monoclonal component that displays a rheumatoid factor activity capable of reacting with intact IgG and/or its F(ab)2′ fragment [42–44]. RF may be present in up to 50–85% of chronic HCV patients [16, 20].

Our data indicated a statistically significant increase in RF concentration in groups IIa and IIb compared to the control group. This finding is supported by many researchers who reported the relationship between HCV infection and higher RF [20, 45].

Cystatin C is a non-glycosylated protein and freely filtered at the glomerulus, but it is metabolized in the proximal tubules so its clearance cannot be calculated [46]. Moreover, cystatin C has a shorter half-life [47] and provided an early prediction of kidney dysfunction in coronary heart diseases in spite of a normal serum creatinine level [48]. Serum cystatin C is increased with

| Table 2 | ROC curve, sensitivity, specificity, and accuracy of cystatin C and creatinine/cystatin C ratio levels to determine susceptibility and risk of kidney injury among groups |
|---------|---------------------------------------------------------------|
| Cystatin C (mg/L)                  | Creatinine/cystatin C ratio (μMol/mg)                       |
| AUC    | 0.864                                                        |
| P value| 0.001*                                                       |
| 95% CI | 0.775–0.952                                                  |
| Cutoff point | 1.24                                                          |
| Sensitivity | 76.7 %                                                      |
| Specificity | 70%                                                          |

AUC area under the curve, CI confidence interval

---

![Fig. 1](image.png)

**Fig. 1** ROC curves of cystatin C in HCV-infected patients (A). ROC curves of creatinine/cystatin C in HCV-infected patients (B)
the progression of chronic viral hepatitis C as a potential marker for liver inflammation and fibrosis [8, 9, 28]. Our data indicated a statistically significant increase in cystatin C concentration in both groups IIa and IIb as compared to the control group. HCV-infected patients had significantly higher serum cystatin C (> 1.24 mg/L) and lower creatinine/cystatin C ratio (< 70.1 μMol/mg) and was correlated with renal function and extrahepatic cryoglobulins and RF and complement C3 parameters. This finding may be supported by many studies that reported the relationship between HCV infection and serum cystatin C [8–10]. The creatinine/cystatin C ratio or creatinine/cystatin C × 100 was an indicator to sarcopenia index (SI) for the prediction of liver injury and sarcopenia in liver disease [22] and monitoring the progression of non-alcoholic fatty liver disease [21]. Therefore, serum cystatin C may be more sensitive than serum creatinine in detecting earlier stages of renal dysfunction among HCV-infected individuals. Also, the elevated serum cystatin C found in the present study may be either related to hepatic and/or renal affection in HCV-infected patients with normal renal function test.

**Table 3** Correlation between variables

| Variable                                      | Cystatin C (mg/L) | Creatinine/cystatin C (μMol/mg) |
|-----------------------------------------------|-------------------|---------------------------------|
| Serum total bilirubin (mg/dL)                 | \( r = 0.711 \)   | \( P \text{ value} = 0.001^* \) |
|                                               |                   | \( -0.418 \)                     |
| Serum alanine transaminase (ALT) (U/L)        | \( r = 0.720 \)   | \( P \text{ value} = 0.001^* \) |
|                                               |                   | \( -0.516 \)                     |
| Serum aspartate transaminase (AST) (U/L)      | \( r = 0.741 \)   | \( P \text{ value} = 0.001^* \) |
|                                               |                   | \( -0.559 \)                     |
| Serum albumin (g/dL)                          | \( r = -0.647 \)  | \( P \text{ value} = 0.001^* \) |
|                                               |                   | \( 0.444 \)                      |
| Blood urea nitrogen (BUN) (mg/dL)             | \( r = 0.249 \)   | \( P \text{ value} = 0.018^* \) |
|                                               |                   | \( -0.077 \)                     |
| Creatinine (mg/dL)                            | \( r = 0.454 \)   | \( P \text{ value} = 0.029 \)   |
| Creatinine clearance (mL/min)                 | \( r = -0.186 \)  | \( P \text{ value} = 0.134 \)   |
| Urine albumin/creatinine ratio (mg/g)         | \( r = 0.678 \)   | \( P \text{ value} = 0.001^* \) |
|                                               |                   | \( -0.488 \)                     |
| Serum cryoglobulins (ng/mL)                   | \( r = 0.446 \)   | \( P \text{ value} = 0.011^* \) |
|                                               |                   | \( -0.374 \)                     |
| Complement C3 (mg/dL)                         | \( r = -0.435 \)  | \( P \text{ value} = 0.018^* \) |
|                                               |                   | \( 0.527 \)                      |
| Rheumatoid factor (IU/mL)                     | \( r = 0.511 \)   | \( P \text{ value} = 0.008^* \) |
|                                               |                   | \( -0.448 \)                     |
| Serum cystatin C (mg/L)                       | \( r = -0.766 \)  | \( P \text{ value} = 0.001^* \) |

*\( P \) was significant if < 0.05. \( r = \) correlation

**Conclusion**

HCV is an infectious disease that causes acute hepatitis C and may progress to chronic HCV manifested by increased serum total bilirubin, ALT, and AST and reduced serum albumin. Our HCV patients had many causes and not only a sign of renal impairment with slightly increased serum creatinine and BUN levels, but their levels were still within normal range. HCV-infected patients had an increased level of urine albumin/creatinine ratio and reduced creatinine clearance levels. Our HCV patients have many causes and not only a sign of renal impairment, and their analysis was not out of the normal range. The extrahepatic manifestations of HCV lead to increase serum cystatin C and cryoglobulins and RF levels but also reduced creatinine/cystatin C ratio (< 70.1 μMol/mg) was correlated with renal function and extrahepatic laboratory investigations in newly HCV-infected patients with normal renal function test.
Limitations of study
More advanced and expanded studies are recommended on a larger number of patients including their clinical data and complaints to get a better evaluation and to clarify the correlation of cystatin C in patients with HCV on early renal impairment (clinical and advanced renal investigatory parameters) as extrahepatic manifestation.

Acknowledgements
The authors would like to express deep appreciations and thanks to Dr. Ziad Elmadbouh (Faculty of Medicine, October 6 University) for analyzing statistical parameters and editing of the manuscript. Also, the authors thank the Medical Research Institute (MRI), Alexandria University and Central Laboratory Unit, Faculty of Medicine, Mansoura University, for providing us with the necessary instruments for the completion of the study.

Authors’ contributions
NMA, AIM, and IE: contributed to the study concept, design, clinical investigations, methodology, data collection, statistical analysis, and interpretation of the data. IE, IE, and HMA: supervision and conceptualization in the study. All authors contributed to writing and critically revised and finalized the paper, and all authors read and approved the final manuscript.

Funding
There has been no financial support for this work that could have influenced its outcome.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Patients were enrolled in the study after obtaining their written informed consent and approval from the Ethics Committee of Menoufia University Hospital. The committee’s reference number is not available.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria, Egypt. 2 Chemistry Department, Faculty of Science, Menoufia University, Shebin El Kom, Egypt. 3 Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Menoufia University, Shebin El Kom, Egypt.

Received: 2 April 2022 Accepted: 15 November 2022 Published online: 24 November 2022

References
1. Gower E, Estes C, Blach S et al (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61(1 Suppl):S45–S57
2. Stanaway JD, Flaxman AD, Naghavi M et al (2016) The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388(10049):1081–1088
3. Lee JJ, Lin MY, Chang JS et al (2014) Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One 9(6) e100790
4. Fabrizi F, Dixo V, Messa P (2012) Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat 19(9):601–607
5. Ferguson TW, Komenda P, Tangri N (2015) Cystatin C as a biomarker for estimating glomerular filtration rate. Curr Opin Nephrol Hypertens 24(3):295–300
6. Tangri N, Stevens LA, Schmid CH et al (2011) Changes in dietary protein intake has no effect on serum cystatin C levels independent of the glomerular filtration rate. Kidney Int 79(4):471–477
7. Stevens LA, Coresh J, Greene T et al (2008) Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 354(23):2473–2483
8. Zheng H, Liu H, Hao A et al (2020) Association between serum cystatin C and renal injury in patients with chronic hepatitis B. Medicine (Baltimore) 99(32):e21551
9. Ladreno JM, Cardenas MC, Ortega L et al (2012) Serum cystatin C: a non-invasive marker of liver fibrosis or of current liver fibrogenesis in chronic hepatitis C? Ann Hepatol 11(5):648–651
10. Behairy RE, Saber MA, Elhenawy IA et al (2012) Serum cystatin C correlates negatively with viral load in treatment-naive children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 54(3):364–368
11. Francoz C, Glotz D, Moreau R et al (2010) The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 52(4):605–613
12. Maiz WL, Liu S, Wang K et al (2020) Cystatin C in evaluating renal function in ureteral calculi hydropnephrosis in adults. Kidney Blood Press Res 45(1):109–121
13. Pei XH, He J, Liu Q et al (2012) Evaluation of serum creatinine- and cystatin C-based equations for the estimation of glomerular filtration rate in a Chinese population. Scand J Urol Nephrol 46(3):223–231
14. Holers VM (2014) Complement and its receptors: new insights into human disease. Annu Rev Immunol 32:433–459
15. Kim H, Meyer K, Di Bisceglie AM et al (2013) Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function. J Virol 87(10):5858–5867
16. Borman M, Swain MG (2011) Hepatitis C virus treatment complicated by rheumatoid arthritis. Gastroenterol Hepatol (N Y) 7(11):774–776
17. Ramos-Casals M, Stone JH, Cid MC et al (2012) The cryoglobulinemias. Lancet 379(9813):348–360
18. Sung KC, Ryu S, Lee JY et al (2016) Urine albumin/creatinine ratio below 30 mg/g is a predictor of incident hypertension and cardiovascular mortality. J Am Heart Assoc 5(9):e003245
19. Himoto T, Hirakawa E, Fujita K et al (2019) Complement component 3 as a surrogate hallmark for metabolic abnormalities in patients with chronic hepatitis C. Ann Clin Lab Sci 49(1):79–88
20. Cheng YT, Cheng JS, Lin CH et al (2020) Rheumatoid factor and immunoglobulin M mark hepatitis C-associated mixed cryoglobulinemia: an 8-year prospective study. Clin Microbiol Infect 26(3):366–372
21. Li S, Lu J, Gu G et al (2021) Serum creatinine-to-cystatin C ratio in the progression monitoring of non-alcoholic fatty liver disease. Front Physiol 12:664100
22. Ichikawa T, Miyaki K, Mima S et al (2020) Indices calculated by serum creatinine and cystatin C as predictors of liver damage, muscle strength and sarcopenia in liver disease. Biomed Rep 12:89–98
23. Moreau R, Jalan R, Gines P et al (2013) Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144(7):1426–1437
24. Tsien CD, Rabie R, Wong F (2013) Acute kidney injury in decompensated cirrhosis. Gut 62(1):131–137
25. Roccatoletto D, Fornasier E, Giachino O et al (2007) Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney D 49(1):69–82
26. Beddu S, Bastacky S, Johnson JP (2002) The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore) 81(5):398–409
27. Sansonno D, Lauletta G, Nisi L et al (2003) Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinemia. Clin Exp Immunol 133(2):275–282
28. Chu SC, Wang CP, Chang YH et al (2004) Increased cystatin C serum concentrations in patients with hepatic diseases of various severities. Clin Chim Acta 341(1–2):133–138
29. Authier FJ, Pawlotsky JM, Viard JP et al (1993) High incidence of hepatitis C virus infection in patients with cryoglobulinemic neuropathy. Ann Neurol 34(5):749–750.
30. Desbois AC, Cacoub P, Saadoun D (2019) Cryoglobulinemia: an update in 2019. Joint Bone Spine 86(6):707–713.
31. Dammacco F, Laulette G, Russi S et al (2019) Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. Clin Exp Med 19(1):1–21.
32. Kolopp-Sarda MN, Miossec P (2020) Contribution of Hepatitis C infection to a large cohort of cryoglobulin-positive patients: detection and characteristics. Front Immunol 11:1183.
33. Angeletti A, Cantarelli C, Cravedi P (1993) HCV-associated nephropathies in the era of direct acting antiviral agents. Front Med (Lausanne) 6:20.
34. Pelletier K, Royal V, Mongeau F et al (2019) Persistent mixed cryoglobulinemia despite successful treatment of hepatitis C, aggressive B-cell-directed therapies, and long-term plasma exchange. Kidney Int Rep 4(8):1194–1198.
35. Karthi V, Franco L, Coventry S et al (2018) Hepatitis C mixed cryoglobulinemia with undetectable viral load: a case series. JAAD Case Rep 4(7):684–687.
36. Ricklin D, Haji-shengallis G, Yang K et al (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11(9):785–797.
37. Mazumdar B, Kim H, Meyer K et al (2012) Hepatitis C virus proteins inhibit C3 complement production. J Virol 86(4):2221–2228.
38. Chang ML, Hu JH, Chen WT et al (2021) Interactive impacts from hepatitis C virus infection and mixed cryoglobulinemia on complement levels. Dig Dis Sci 66(7):2407–2416.
39. Maloney BE, Perera KD, Saunders DRD et al (2020) Interactions of viruses and the humoral innate immune response. Clin Immunol 212:108351.
40. El-Shamy A, Branch AD, Schiano TD et al (2018) The complement system and C1q in chronic hepatitis C virus infection and mixed cryoglobulinemia. Front Immunol 9:1001.
41. El-Fatah Fahmy Hanno A, Mohiedeen KM, Deghedy A et al (2014) Serum complements C3 and C4 in chronic HCV infection and their correlation with response to pegylated interferon and ribavirin treatment. Arab J Gastroenterol 15(2):58–62.
42. Matignon M, Cacoub P, Colombat M et al (2009) Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection. Medicine (Baltimore) 88(6):341–348.
43. Alpers CE, Smith KD (2008) Cryoglobulinemia and renal disease. Curr Opin Nephrol Hypertens 17(3):243–249.
44. Sansonno D, Dammacco F (2005) Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 5(4):227–236.
45. Tung CH, Lai NS, Li CY et al (2018) Risk of rheumatoid arthritis in patients with hepatitis C virus infection receiving interferon-based therapy: a retrospective cohort study using the Taiwanese national claims database. BMJ Open 8(7):e021747.
46. Peralta CA, Shlipak MG, Judd S et al (2011) Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 305(15):1545–1552.
47. Krstic D, Tomic N, Radosavljevic B et al (2016) Biochemical markers of renal function. Curr Med Chem 23(19):2018–2040.
48. Zhao R, Li Y, Dai W (2016) Serum cystatin C and the risk of coronary heart disease in ethnic Chinese patients with normal renal function. Lab Med 47(1):13–19.